

Strides Pharma's Singapore arm receives USFDA nod for painkiller capsule Celecox

The drug has a combined market size of around Rs 1,000 crore in the US, and the Indian drugmaker will manufacture it at its Puducherry facility.



Bengaluru: Strides Pharma Science Limited's step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval from the United States Food and Drug

Administration (USFDA) for Celecoxib Capsules, 1 mg.

Celecoxib is a selective COX-2 inhibitor used for the management of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea.

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Celebrex Capsules, marketed by Upjohn, which has a combined market size of \$116 million (around ₹1,000 crore) in the US.

According to the company release, the product will be manufactured at the company's Puducherry facility.

News Source:

https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/strides-pharmas-singapore-arm-receives-usfda-nod-for-painkiller-capsule-celecoxib/120786900?utm_source=whatsapp_web&utm_medium=social&utm_campaign=socialsharebuttons